Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

The accelerated approval is based on phase 2 data demonstrating that Leqembi reduced the accumulation of amyloid in the brain, although interim results from the phase 3 CLARITY-AD study revealed a ...

The UK drugs regulator has approved Eisai and Biogen's Alzheimer's disease therapy Leqembi, shortly after an EU committee turned it down on the grounds that its modest efficacy did not outweigh ...